GSK (GSK) stock was downgraded by Guggenheim Securities to neutral after the company's Q3 revenue decline. Read more here.

In a report released today, Emily Field from Barclays maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a price target of £14.50 ... corporate insider sentiment is positive on ...

GSK reports Q3 sales of $10.42 billion, missing estimates due to an 18% drop in vaccine revenue, while specialty medicines ...

This writer thinks GSK shares appear very cheap after the Q3 results, making him wonder if now's the time for him to invest ...

GSK plc (LON:GSK – Get Free Report) insider Jonathan Symonds bought 7,150 shares of the stock in a transaction dated ...

Shares of GlaxoSmithKline (GSK) Pharmaceuticals surged up to 3.4 per cent at Rs 2719.90 per share on the BSE in Wednesday’s ...

GSK plc GSK reported third-quarter 2024 core ... The upside was partially offset by the removal of the Average Manufacturer Price cap on Medicaid drug prices in the United States, adversely ...

GSK's shares are falling 4% in premarket trading Wednesday after the British pharma giant posted lower-than-estimated quarterly sales and lowered its projection for vaccine sales ...

In the third quarter, GSK saw weaker-than-expected sales for its respiratory syncytial virus (RSV) and shingles vaccines.

Haleon (HLN) share price has retreated in the past few weeks, erasing some of the gains made earlier this year. Its London ...

GSK said it acquired an experimental therapy from Chimagen Biosciences that it aims to test in different forms of lupus, and ...

The firm has removed its price target for GSK, previously set to guide investors on the stock's potential value. The downgrade reflects concerns about the limited upside in the company's pipeline ...